For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230906:nRSF5639La&default-theme=true
RNS Number : 5639L Bank of America Merrill Lynch 06 September 2023
FORM 38.5(b)
IRISH TAKEOVER PANEL
DISCLOSURE UNDER RULE 38.5(b) OF THE IRISH TAKEOVER PANEL ACT, 1997,
TAKEOVER RULES, 2013
DEALINGS BY CONNECTED EXEMPT PRINCIPAL TRADERS WITHOUT
RECOGNISED INTERMEDIARY STATUS, OR WITH RECOGNIZED INTERMEDIARY
STATUS BUT NOT DEALING IN A CLIENT-SERVING CAPACITY
1. KEY INFORMATION
Name of exempt principal trader BofA Securities, Inc.
Company dealt in HORIZON THERAPEUTICS PLC
Class of relevant security to which the Common - IE00BQPVQZ61
dealings being disclosed relate(Note 1)
Date of dealing 05/09/2023
BofA Securities, Inc.
Company dealt in
HORIZON THERAPEUTICS PLC
Class of relevant security to which the
dealings being disclosed relate(Note 1)
Common - IE00BQPVQZ61
Date of dealing
05/09/2023
2. INTERESTS AND SHORT POSITIONS
(a) Interests and short positions (following dealing) in the class of relevant
security
dealt in (Note 2)
Class of relevant security: Common IE00BQPVQZ61
Long Short
Number % Number %
(1) Relevant securities 274,747 0.120% 110,450 0.048%
(2) Derivatives (other than options): 167,407 0.073% 60,931 0.027%
(3) Options and agreements to purchase/sell: 50,000 0.022% 19,500 0.009%
Total 492,154 0.215% 190,881 0.084%
274,747
0.120%
110,450
0.048%
(2) Derivatives (other than options):
167,407
0.073%
60,931
0.027%
(3) Options and agreements to purchase/sell:
50,000
0.022%
19,500
0.009%
Total
492,154
0.215%
190,881
0.084%
(b) Interests and short positions in relevant securities of the company, other
than the
class dealt in (Note 2)
Class of relevant security:
Long Short
Number % Number %
(1) Relevant securities 0 0% 0 0%
(2) Derivatives (other than options): 0 0% 0 0%
(3) Options and agreements to purchase/sell: 0 0% 0 0%
Total 0 0% 0 0%
0
0%
0
0%
(2) Derivatives (other than options):
0
0%
0
0%
(3) Options and agreements to purchase/sell:
0
0%
0
0%
Total
0
0%
0
0%
3. DEALINGS (Note 3)
(a) Purchases and sales
Purchase/sale Number of relevant securities Price per unit (Note 4)
Purchase 2,406 115.53 USD
Purchase 858 115.54 USD
Purchase 300 115.455 USD
Purchase 4,705 115.46 USD
Purchase 4,007 115.47 USD
Purchase 1,000 115.465 USD
Purchase 4,422 115.48 USD
Purchase 600 115.505 USD
Purchase 7,901 115.5 USD
Purchase 8,302 115.49 USD
Purchase 2,274 115.495 USD
Purchase 1,400 115.475 USD
Purchase 10,733 115.51 USD
Purchase 4,095 115.485 USD
Purchase 1,908 115.52 USD
Purchase 300 115.525 USD
Purchase 5 115.486 USD
Purchase 100 115.473 USD
Purchase/sale Number of relevant securities Price per unit (Note 4)
Sale 6 115.55 USD
Sale 21 115.46 USD
Sale 134 115.47 USD
Sale 65 115.48 USD
Sale 46 115.5 USD
Sale 76 115.49 USD
Sale 46 115.495 USD
Sale 2 115.475 USD
Sale 9 115.51 USD
Sale 6 115.485 USD
Sale 2 115.52 USD
(b) Derivatives transactions (other than options transactions)
Product name, Nature of transaction Number of relevant securities Price per unit
e.g. CFD
(Note 5) (Note 6)
(Note 4)
Swaps Increasing a Long Position 1 115.49 USD
(c) Options transactions in respect of existing relevant securities
(i) Writing, selling, purchasing or varying
Product name, e.g. call option Writing, selling, purchasing, varying etc. Number of securities to which the option relates (Note 7) Exercise price Type, e.g. American, European etc Expiry date Option money paid/ received per unit (Note 4)
N/A N/A N/A N/A N/A N/A N/A
(ii) Exercising
Product name, Number of securities Exercise price per
e.g. call option
unit (Note 4)
N/A N/A N/A
(d) Other dealings (including transactions in respect of new securities) (Note 3)
Nature or transaction Details Price per unit
(Note 7)
(if applicable) (Note 4)
Borrow Borrow of 1,481 shares N/A
Loan Loan of 1,481 shares N/A
4. OTHER INFORMATION
Agreements, arrangements or understandings relating to options or derivatives
Full details of any agreement, arrangement or understanding between the person
disclosing and any other person relating to the voting rights of any relevant
securities under any option referred to on this form or relating to the voting
rights
or future acquisition or disposal of any relevant securities to which any
derivative
referred to on this form is referenced. If none, this should be stated.
None
Is a Supplemental Form 38.5(b) attached? (Note 8) No
Date of disclosure 06/09/2023
Contact name Frank Lui
Telephone number +44207 996 6418
Name of offeree/offeror with which connected AMGEN INC
Nature of connection (Note 9) Advisor to - AMGEN INC
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
or visit
www.rns.com (http://www.rns.com/)
.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
. END ITPZZGGLLVNGFZG